Free Psychiatry CME

  • FREE

    Free Psychiatry CME Courses from Pri-Med® – Designed for Primary Care Clinicians

    Individuals with depression, anxiety, bipolar disorder, and other psychiatric conditions first seek help from primary care providers like you. Our courses offer practical guidance on assessing and managing these can’t-miss diagnoses in your patients. Choose from a variety of free psychiatry CME courses to improve care for your patients. Earn credits at no cost today.

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies by Course
    • CME credits awarded by: pmiCME, the accredited division of Pri-Med®
    • Format: On-Demand Courses Online
    • Material last updated: Continuously Updated
    • Expiration of CME credit: Varies by Course
  • FREE

    Fact or Fiction? Test Your Knowledge on Residual and Treatment-Emergent Symptoms in Major Depressive Disorder

    Although major depressive disorder (MDD) has a profound impact on individuals, families, and society, it remains undertreated. There are currently more than 4 million US adults who are inadequately treated for MDD. Numerous studies show that antidepressant therapies are superior to placebo, but most adults with MDD do not achieve an adequate response with first-line pharmacotherapy. Inadequate response to antidepressant therapy is associated with greater medical morbidity, more hospitalizations, decreased productivity, and more suicide attempts. Treatment of MDD should strive for return to premorbid status and full functional and cognitive recovery. However, survey data show that health care providers may lack confidence in the management of patients who have an inadequate response to an antidepressant. The major barriers to achieving full recovery are the continuation of residual symptoms and treatment-emergent symptoms associated with antidepressants. Even in those responding to antidepressants, residual and treatment-emergent symptoms such as weight gain, sleep disturbance, and sexual dysfunction can impede adherence and recovery. Additionally, poor cognitive functioning is an obstacle to remission. Although tools are available for the evaluation and monitoring of cognitive function in patients with MDD, they remain underutilized. In this enduring activity, expert faculty will provide opportunities to enhance knowledge and competence in the ability to differentiate residual and treatment-emergent symptoms and better assess and manage symptoms using evidence-based strategies to optimize available therapies.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: Medical Education Resources
    • Format: On-Demand Online
  • FREE

    Fact or Fiction? Test Your Knowledge on Assessment and Management Strategies in Tardive Dyskinesia

    At any given time, roughly one-quarter of individuals taking antipsychotics experience TD, a condition characterized by involuntary movements of the face and body. Moreover, as the use of antipsychotics has expanded to disorders such as depression, behavioral disorders, and dementia, TD is no longer primarily limited to patients with schizophrenia. TD has an outsized impact on patients’ ability to carry out daily tasks and interact with others. However, because TD has long been considered an irreversible consequence of the use of antipsychotics or other dopamine receptor–blocking agents, many clinicians have come to view it with a sort of “therapeutic nihilism.” As a result, many patients have not received treatment for their TD. Recently, the US FDA approved 2 medications, both vesicular monoamine transporter 2 (VMAT2) inhibitors, to treat TD, giving patients access to the first well-tolerated oral treatments shown to be effective for this condition. To ensure that patients receive maximum benefit from this advance in TD treatment, clinicians must learn how to integrate VMAT2 inhibitors into their practice. In this activity, an expert faculty member will dispel common myths about TD, educating clinicians about how to recognize and diagnose TD promptly, how VMAT2 inhibitors work to improve TD symptoms, how the 2 approved agents differ, and how VMAT2 inhibitors can be used alongside other strategies to improve outcomes for patients with TD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: Medical Education Resources
    • Format: On-Demand Online
  • FREE

    One Size Does Not Fit All: Optimizing Use of Major Depressive Disorder Specifiers to Improve Outcomes

    Major depressive disorder (MDD) is a highly heterogeneous disorder that is increasingly seen as a continuum, with emphasis on overlapping and subthreshold symptoms. To address this issue, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) included the use of specifiers, such as mixed features and anxious distress, with the diagnosis of MDD. Although DSM-5 specifiers improve utility and precision in the diagnosis of MDD and related disorders, they may not be widely adopted because some clinicians maintain a categorical approach toward depression. The risk when clinicians avoid specifiers is significant because patients with diverse depressive illnesses should be diagnosed, monitored, and treated differently. Further, compared with MDD alone, the presence of mixed features or anxious distress in patients with MDD may be associated with diminished response to antidepressants, more severe symptoms, increased hospitalization, greater risk for suicide, and other deleterious outcomes. It is important for health care providers to appreciate the importance of MDD specifiers, their diagnostic criteria, and implications for evidence-based treatment. This activity was created to enhance knowledge and competence of health care providers who evaluate and manage patients with depression and clinical features of hypomania, mania, or anxiety.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.5
    • CME credits awarded by: Medical Education Resources
    • Format: On demand online
  • FREE

    Best Practices and Advanced Treatment Strategies in Bipolar Disorder Pharmacotherapy

    Bipolar disorder is a mood disorder characterized by episodes of mania, hypomania, and depression. It affects 3-4% of the U.S. population, represents a substantial societal and economic burden in the United States.

    By the end of Best Practices and Advanced Treatment Strategies in Bipolar Disorder Pharmacotherapy, you will be able to:
    • Describe the pathophysiology of bipolar disorder and the role the neurotransmitters play in them
    • Describe the benefits and risks of pharmacotherapy for patients presenting with bipolar disorder and take them into account when formulating treatment plans for patients.
    • Recommend therapy changes in patients with bipolar disorder who are unable to tolerate a prescribed treatment
    • Identify barriers to care in patients with bipolar disorder and develop strategies to abate them

    Target Audience:
    Family medicine, internal medicine, mental health, neurology and psychiatry, or those who otherwise commonly care for patients with bipolar or related psychiatric diseases.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 0.75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online, Online Video
    • Material last updated: February 02, 2018
    • Expiration of CME credit: February 02, 2020
  • FREE

    Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices

    Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices covers the epidemiology, diagnosis and treatment of Alcohol Use Disorder and consists of a single lecture by Timothy Fong MD.

    After participating in Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices , you will be able to:
    • Describe the epidemiology of AUD and outline current and evolving diagnostic criteria
    • Describe challenges to the successful identification of patients with AUD
    • Identify the treatment modalities currently available for management of AUD and apply them to patient cases using evidence-based medicine
    • Develop strategies for recognizing and improving therapeutic adherence in patients treated for AUD

    Target Audience:
    Psychiatrists, primary care physicians, emergency medicine physicians, physician assistants, nurse practitioners, pharmacists, and those healthcare professionals who commonly treat patients suffering from or have a clinical interest in AUD.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: October 13, 2017
    • Expiration of CME credit: October 13, 2019
  • FREE

    Major Depressive Disorder (MDD): Updates from the American Psychiatric Association Annual Meeting (APA) 2017

    Major Depressive Disorder (MDD): Updates from the American Psychiatric Association Annual Meeting (APA) 2017 includes major findings about major depressive disorder from APA 2017, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice.

    After reviewing Major Depressive Disorder (MDD), you will be able to:
    • Recall the most impactful findings about Major Depressive Disorder (MDD) from the APA 2017 Annual meeting relating to MDD pathophysiology, progression, & prognosis.
    • Describe the most impactful findings about MDD from the APA 2017 Annual meeting relating to using the similarities & differences between MDD & bereavement to inform good clinical care.
    • Summarize the most impactful findings about MDD from the APA 2017 Annual meeting relating to old, new, emerging, and potential new targets for treating of MDD and apply them to patient cases.

    Target Audience:
    Healthcare professionals specializing in family medicine, internal medicine, mental health, neurology and psychiatry, or those who otherwise commonly care for patients with MDD or related psychiatric diseases.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 18, 2017
    • Expiration of CME credit: July 18, 2019
  • FREE

    Schizophrenia: Updates from the American Psychiatric Association Annual Meeting 2017

    Schizophrenia: Updates from the American Psychiatric Association Annual Meeting 2017, including clinical trial data relevant to both community and health-system practice and recognized barriers to implementing those findings in practice.

    After viewing Schizophrenia: Updates from the American Psychiatric Association Annual Meeting, you will be able to:
    • Recall the most impactful findings about Schizophrenia from the APA 2017 Annual meeting relating to schizophrenia pathophysiology, progression, & prognosis.
    • Describe the most impactful findings about schizophrenia from the APA 2017 Annual meeting relating to using the similarities & differences between schizophrenia & other disorders to inform good clinical care.
    • Summarize the most impactful findings about schizophrenia from the APA 2017 Annual meeting relating to old, new, emerging, and potential new targets for treating of schizophrenia and apply them to patient cases.

    Target Audiences:
    Healthcare professionals specializing in family medicine, internal medicine, mental health, pediatric neurology and psychiatry, or those who otherwise commonly care for patients with dchizophrenia or related psychiatric diseases.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: July 27, 2017
    • Expiration of CME credit: July 27, 2019
  • FREE

    Scientia CME Neuropsychiatry – Psychiatry

    • Cost: Free
    • Credit hours: 2
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release
  • FREE

    Binge Eating Disorder (BED): Therapeutic Updates, Best Practices, and Barriers to Care

    This free online CME self-learning program provides deep insights into Binge Eating Disorder (BED) and features commentary from experts on the topic.

    Topics covered in this program include

    • BED epidemiology
    • BED comorbidities
    • BED treatment
    • BED diagnosis

    After completing this course, you will better be able to:

    • Describe the importance of accurate diagnosis and treatment of BED.
    • Determine likelihood of BED using established methods in a patient case.
    • Describe available therapies used for treatment of BED and summarize* recent literature supporting use of those therapies
    • Design a therapeutic regimen, including pharmacotherapy, for the treatment of BED
    • Describe barriers preventing the optimal treatment of BED

    Target Audience: Psychiatrists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in psychiatry; and any other healthcare professionals with an interest in or who clinically encounter patients with BED.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: September 04, 2018
    • Expiration of CME credit: September 04, 2021